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By letter of 20 November 1985 the Committee on Energyp Rese~rch ~nd Technology 
requested @Uthorization to draw up~ report on biotechnology in Europe and th~ 
need for an integrated policy@ 
By letter of 10 December 1985 the Committee on Energy, Research and Technology 
was authorized to draw up~ report on this subj~cta The Committee on 
Agriculture# fisheries and foodp the Committee on Economic and Monetary 
Affairs and Industrial Policyp the Committee on Legal Affairs and Citizens
0 
Rights, the Committee on Social Affairs and Employment and th~ Committee on 
the Environmentu Public Health and Consumer Protection were asked for opinions~ 
On 23 April 1985 the Committee on Energy, Research ~nd TEchnology also decided 
to include in its report ~ll the motions for resolutions on biotechnology 
referred to it pursuint to ~ule 47 of the Rules of Procedure 9 n1mely the 
motions for resolutions tabled by Mr ROUX and others (Doc~ B 2-579/85)§ 
Mr TOLMAN and Mr EVRAUD (Dots B 2-1087/86) and Mr PEARCE (Docs B 2-1162/SS)G 
The tommittee considered the draft report at its meetings of 24 febru~ry, 
28 Mayu 22 June and 17 September 1986a The motion for~ resolution as a ~hole 
Mas adopted on 14 October 1986 by 18 votes to 2 with 2 abstentions~ 
The following took p~rt in the vote: Mr PONIATOWSKiu thairm~n; Mr S~LZER, 
Mr ADAM and Mr SELIGMANP vice-thairmen; Mrs V!EHOffp rapporteur; Mr BLUMu 
Mrs d0 ANCONA (deputizing for ~rs Lizin)# Mr GAUTHIER, Mr H~RllN (deputizing 
for Mr TRIDENTE)p Mr KOLOKOTRONIS, Mrs LIENE~ANN~ Mr LINKOHRR ~r MALLET§ 
Mr METTEN (deputizing for ~r SMlTH) 6 Mr PETERS (d~putizing for Mr WEST)u 
Mr RINSCHE§ Mr StHINIElp Mr SHERLOCK (deputizing for ~r TOKSVIG) 1nd Mr ~ElTIG 
(deputizing for Mr SANZ-fERNANDEZ)s 
The opinions of the ComMitte~ on Agriculture~ fisheries and foodu the 
Committee on Economic and Monetary Affairs and Industrial Policy9 the 
Committee on Legal Affairs and Citizens 8 Rights and the Committee on the 
Environment
1 
Public H~alth and Consumer Protection ~re attached~ 
The opinion of the Committee on Social Affairs ~nd Employment will be 
published separately~ 
The report was tabled on 24 October 1986~ 
The deadline for tabling ~mendments to this report will be indicated in the 
draft agenda for the p~rt=session at which it ~ill be debatedQ 
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The Committee on Energy, Research and Technology hereby submits to the 
European Parliament the following motion for a resolution together with 
explanatory statement: 
A 
MOTION FOR A RESOLUTION 
on biotechnology in Europe and the need for an integrated policy 
The European Parliament, 
- having regard to the communication from the Commission to the Council 
concerning the review of the multiannual research programme for the EEC in 
the field of biotechnology (1985-1989) (COM(86) 272 final), 
- having regard to the discussion paper of the Commission 'Biotechnology in 
the Community: Stimulating Agro-Industrial Development• CCOM(86) 221 final), 
- having regard to the motions for resolutions by Mr ROUX and others on 
research in the field of biotechnology (Doc. B 2-579/85), by Mr TOlMANN and 
Mr EYRAUD on the use of agricultural products in biotechnology 
(Doc~ B 2-1087/85) and by Mr PEARCE on developments in the manufacture of 
hormones (Doc. B 2-1162/85), 
- having regard to the report of the Committee on Energy, Research and 
Technology and the opinions of the Committee on Agriculture, Fisheries and 
Food, the Committee on Economic and Monetary Affairs and Industrial Policy, 
the Committee on Legal Affairs and Citizensu Rights, the Committee on Social 
Affairs and Employment and the Committee on the Environment, Public Health 
and Consumer Protection (Doc. A 2-134/86), 
Aa whereas the complexity of biotechnology research requires a 
multidisciplinary and integrated approach which goes far beyond the 
financial and research potentials of the individual Member States of the 
Community, 
B. in view of the considerable success of the first European Biomolecular 
Engineering Programme (BEP) in stimulating transnational cooperation 
between European laboratories and the training of young scientists as well 
as coordinating research activities, although BEP had only a limited 
budget and concentrated mainly on research connected with agriculture and 
the food processing industry, 
C. recognizing that since the start of the Biotechnology Action Programme 
(BAP) in 1985 new and broader areas of research are covered and that this 
programme was received with overwhelming interest both from industry and 
research laboratories, resulting in more than 1 300 project applicationsp 
of which, however, more than 80% had to be turned down because of the 
restricted budgetary provisions of the four-year-programme, 
Dg warning that further neglect of applications for highly promising projects 
may well make European laboratories less willing to cooperate, 
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E8 aware of the positive effects a more substantial financial endowment of 
the BAP would have as regards 
- the development of socially useful products, 
- the extension of scientific exchange and training facilities especially 
for the less-advanced countries in the Community, 
= the expansion into those important research areas where Europe is 
lagging behind the USA and Japan, such as bioinformatics, protein design 
and plant biochemistry, 
F. determined that the social, economic and ecological aspects of new 
developments in the field of biotechnology should be evaluated and 
assessed at the research and development stage, 
Ga recogn1z1ng that, since they did not participate in the first BEP 
programme, the new Member States of the Community should receive 
supplementary aid to enable them to participate in the Biotechnology 
Action Programme (BAP) under optimum conditions, 
H. aware that biotechnology may have some positive effects on the Third World 
but aware also of the predominantly negative effects of the use of 
biotechnology in the industrialized countries on agricultural areas in 
Third World countries, 
1. Asks the Commission to review its biotechnology programme with a view to 
providing the Community with an effective strategic programme that affords 
Europe the means of increasing its competitiveness on world markets 
vis-a-vis Japan and the United States; 
2c Believes that the revised biotechnology programme should specify priority 
fields of action within which research projects will be conducted that 
allow for link-ups between laboratories and European companies; 
3s Believes at all events that the biotechnology programme should involve the 
industrial community as far as possible while remaining,at the stage of 
precompetitive research; 
4. Calls on the Commission to include Parliament's recommendations in its 
proposal for the revision of the programme; 
• 
Sm Stresses the need to establish generally acceptable priorities and better ! 
coordination of the individual research activitie~ of the Member States 
through more comprehensive discussions with interested parties 
(universities, medical authorities and profession, industry) and 
governments upon the instigation of the Commission, and to bring the BAP 
projects more in line with similar projects by other services of the 
Commission (e.g. parts of the Science and Technology for Development 
programme and activities of Directorate-General XIII); 
6. Stresses the importance of the Commission taking action to ensure that 
high priority is given to those projects which contribute to socially 
useful products with high development costs and relatively low profits 
such as 'orphan drugs'; 
WGCVS1)/3858E 
- 6 - PE 105.423/fin. 
• 
7~ Suggests that priority should be given to activities in th~ field of 
health in order to promote research concentrating on the main c1uses of 
death in Europe (cardio-vaseular diseases and cancer); 
8m Stresses the importance of research in the areas of medical biotechnology 
and environmental biotechnology (eDgW degradation of toxic substances)p 
which are under=represented in the current progr~mme; 
9Q Underlines the importance of medical research (in areas such as tropic~l 
diseases, vaccines~ etcQ) and the need for cooperation with Third World 
countries; 
10G Calls for further and up-to-date consideration by interested p~rties 
(universities 0 industry and Member States government expert~)p under the 
aegis of the Commissionu of th~ long-term competitiveness of European 
biotechnology vis-~=vis the USA and Japan and calls for the Commission to 
propose further remedial action; 
116 Expects the Commission to give priority in future to instigating projects 
studying the ~assive release into the environment of g~netically 
engineered natur~l micro-organisms ('deliberate release 0), the 
standardization of varieties and the danger of cultivating the same 
varieties over large areas 9 which should be one of the topics of the FAST 
conference in March 1987; 
12a Asks the Commission to be aware in a general sense of the repercussions of 
each research project on the eenvironment@ and suggests that for each 
research project a sum yet to be determined should be set aside in the 
overall fin1ncial paekag~ for an environmental imp~ct study; 
13s Calls for an assessment of the political and ecological rep~rcussions of 
possible risks of epidemics or any restriction of gene resources and 
suggests a feasibility study for a Europe1n Institute for Ecology; 
14@ Demands that the principles and guidelines of good practice with regard to 
the safety of workers in l~boratories 9 including university and research 
institutes, be strictly respected; 
15~ Welcomes the recent inventory by the Commission's Biotechnology Regulation 
Interservice Committee as an important step towards creating a European 
biotechnology regulation system and calls for harmonization of M~mber 
States@ provisions with regard to safety and the environment to provide 
for common procedures for risk assessment and imposition of conditions at 
! each stage of the development of projects involving micro=organisms 
carrying genetic material and suggests a step-by-step approach for 
regulating the various ph~ses of biotechnology processes (laboratory0 
, trials; limited productionp mass production) and a case-by-case ~pproach 
for approving new .biotechnology products; 
16e Underlines the need for intensive stimulation of research in the field of 
bioinformatics (bio-data banks, inter-laboratory information networksu 
etca) by setting up intensive training and research facilities in 
cooperation with the ESPRIT-programme; 
17m Calls for better and wider dissemination of biotechnological knowledge 
using advanced info-networksu via the BICEPS initiative~ and welcomes 
therefore the planned cooperation of ~G XII and DG XIII; 
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18. Underlines the possible major impact of biotechnology on the future 
development of agriculture, which will bring about important changes in 
agriculture and other related fields, such as the seed industry and 
international trade in commodities; 
19. Calls for an investigation into pricing of agricultural raw materials that 
will be used in biotechnology industry; 
20. Expects special consideration to be given to the possible regional 
disparities resulting from biotechnology especially concerning the 
less-favoured position of the Mediterranean countries and the Third World 
as regards the interface between biotechnology, agriculture and industry, 
as well as the effects of plant substitution on the future agricultural 
orientation of these countries and asks for a follow-up of the Athens 
conference; 
21. Proposes that the BAP programme take into account the possible lower level 
of development attained in Portugal and Spain and grant those countries 
additional resources to enable them to reach the levels attained by those 
countries which have already benefited from the BEP; 
22. Calls for greater coordiantion between the BAP programme and the Science 
and Technology for Development (STD) programme (1987-1990) in the area of 
tropical agriculture and health care and demands easier access to training 
facilities in the Community for scientists and technicians from the Third 
World to enable these countries to develop their own research facilities; 
23. Stresses the need for harmonization of patent law to prevent unfair 
comoetition by ensuring patentability of micro-organisms and ensuring that 
biotechnological innovations receive eQual treatment under the different 
systems of the Member States; 
24. Demands adeauate information of the public on opportunities, risks and 
possibilities of biotechnological research and its application; 
25. Instructs its President to forward this resolution and the report of its 
Committee on Energy, Research and Technology to the Council and Commission. 
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FOREWORD 
Background to the report 
B 
EXPLANATORY STATEMENT 
1. Developments in biotechnology have been looked at on a number of occasions 
in recent years by the European ParliamentQ In the past it was mainly the 
Committee on Energy, Research and Technology which was responsible for drawing 
up reports but now that the results of biotechnology research are rapidly 
finding their way into commercial applications in many sectors of industry, 
agriculture and health careu other parliamentary committees are also being 
obliged to consider the various policy aspects of biotechnology more closelya 
2. The fact that this multidisciplinary technology Mith such a wide range of 
applications has already received the attention of a number of parliamentary 
committees at a relatively early stage is extremely encouragingm The many 
facets and repercussions of biotechnology= from safety provisions to 
employment opportunities and from a policy to encourage research to the 
consequences for the developing countries= call for a specialist approach 
which can best be developed in parliamentary committees with the necessary 
facilitiesm HoweverR to prevent the wide-ranging opportunities and 
conseauences of biotechnology from being subdivided into artificial 
compartments of policy and thus Losing sight of the overall dimension of 
biotechnology, the Committee on Energy, Research and Technology's rapporteur 
for biotechnology has taken the initiative of drawing up this joint reportQ 
3. All the parliamentary committees which could be regarded as concerned by 
biotechnology were asked to deliver opinions making specific policy 
recommendations for the medium and long-term~ This request was acted upon by 
the Committee on the Environment, Public Health and Consumer Protection, the 
Committee on Agriculture, fisheries and Foodp the Committee on Legal Affairs 
and Citizens 0 Rights, the Committee on Social Affairs and Employment and the 
Committee on Economic and Monetary Affairs and Industrial Policya The 
Committee on Social Affairs and Employment had not delivered its definitive 
opinion when this report was being finalized. The Committee on Regional 
Policy and the Committee on Development and Cooperation unfortunately decided 
not to submit contributions butp in view of the political importance of 
biotechnology in these areas of policy, the rapporteur has included in the 
policy guidelines for the Committee on Energy~ Research and Technology, 
recommendations in the area of regional development and development 
cooperation. The two committees have been notified of this decision. 
4. It has thus been possible to combine in this report a large number of 
policy recommendations, opinions and views on biotechnology from various 
committees, as a basis for a wide-ranging debate in the European Parliamento 
As the various contributions demonstrate, there is sometimes conflict or 
overlapping. This can be explained firstly by the differing political 
persuasions of the draftsmen of the opinions and secondly by the fact that 
biotechnology often produces a number of different ~ffects simultaneously 
which are relevant to the ~reas of policy covered by more than one committee. 
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5. This report does not aim to be exhaustive, partly because the necessary 
know-how is not yet available and partly because at the present early stage of 
biotechnology it is not yet possible to cover all its possible effects. In 
addition, there have been earlier reports, such as that by Mr Schmid of 1980 
and the Viehoff report of 19841. The hearings held in November 1985 by the 
Committee on Energy, Research and Technology and by the Committee on Legal 
Affairs and Citizens' Rights also covered ~any aspects of biotechnology whose 
implications for the future of Europe were clarified by experts2. Finally§ 
the Commission of the European Communities, and in particular DG XII through 
its Concertation Unit for Biotechnology in Europe (CUBE) and the Division for 
Genetics and Biotechnology, have published comprehensive reports on 
developments in the area of biotechnology in recent years3. The contents of 
these reports will not be reproduced here. The aim is rather to highlight 
developments resulting from biotechnology which deserve closer study so that 
potential negative effects can be recognized at an early stage and the 
positive effects can be promoted; thus biotechnology presents a real challenge 
to European cooperation. 
I. Introduction 
6. Section II of this report will discuss the significance of biotechnology 
and the need for closer cooperation at European level if Europe is not to be 
left behind in the biotechnology race with the United States and Japana It 
will be argued that although the Biomolecular Engineering Programme CBEP) and 
the current Biotechnology Action Programme CBAP) have laid a solid foundation 
for European cooperation, a massive increase in resources is required to allow 
new promising research projects to be started up and to encourage more 
activities in the area of socially useful but not immediately commercially 
attractive products using biotechnology. 
Section III will then go on to describe what the Committee on Energy, Research 
and Technology regards as the most important policy considerations and issues 
in the medium and long term. Following on from this, Section IV summarizes 
the policy recommendations and research topics suggested by the other 
committees. The full text of the opinions of the various committees is given 
in an annex. 
II. Biotechnology - a challenge to European cooperation 
7. Biotechnology, one of the new key technologies which will radically alter 
existing agro-industrial structures, has received increasing attention at 
national and international level in recent years. Governments in virtually 
all the industrialized countries have set up special biotechnology programmes 
to encourage research and development, with the ultimate goal of improving 
their competitive position. Parallel to this, numerous general measures have 
been taken with the same aim of strengthening the technological base. Lookin~ 
at all these efforts, one can therefore speak of a real biotechnology race. 
However, the participating countries do not all have equal chances in this 
race since their starting positions as regards know-how, industrial base and 
financial resources differ widely. The vast financial input by the US 
Government alone in the area of biotechnology research - a total budget of 
some $2 billion in 1985, with a slight rise to almost $2.1 billion in 1986 and 
1987 - bears no relation to what can be spent by individual European 
countries. Although the available financial resources give some indication o1 
the relative strengths of individual countries, other factors also play an 
4 ~ important role as the example of Japan shows. The Japanese Diet has, for 
example, set up a special commission composed of more than 100 members, the 
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Society of ~iet Me~b~rs fort~~ ~~v@lopm@nt ~nci ~rot~ction of 
Biot~chnology4Q Th~ group is ~h~ir~d by th@ ~ini$t~r of fin~nce 0 ~~ich 
underlines the import~nt~ th~t the J~~~nes® Gov~rnm~nt ~tt~ches to 
biotechnologyo Suth a bro~d=b~sed to~Mi~sion al~o promote~ coordination of 
relev~nt ~r~~s of policy ~nd h@lps to ensure~ broad str~am of information 
down to the low~r levelso Effeetiv~ regul~tion ~nd coordination of rese~rch 
and the @Ctive promotion of ~~l~cti~e cooper~tion b~tween labor~tories and 
industri~l firms ~r@ fyrth~r @~~mples of J~p@n°s inno~~tive m~n~@em~nt ~tyleo 
8~ In the Commission of th~ Europ®~n ComM~niti@~ in r~tent y~~r~ t~~re ~a~ 
been some sig~ of policy ~~~~ur®s to promote bioteth~ologyp ~lt~ough not· 
always in~ fl~~ible ~~YG Although initi~lly@ number of ~emb~r St~tes wer~ 
somewhat reluct~nt to @mb~r~ on~ coordin~ted Europ~~n appro~ch& they now $e~m 
to h~v~ reconsider@d th@ir position since it has b®com® cle~r that it is 
virtually impossible to cre~t® r~pidly ~t n~tion~l l@v~l th~ n~c@ss~ry 
scientific b~se to cov®r th~ wid~=r~nging ~~~ect~ of biotechnologyo The 
comple~ity of biot~ehnology in f~tt r~Quires ~ ~ulticlisciplinary and 
integr~ted appro~eho Xn~i$tent~ on~ n~tion~l ~ppro~ch Me@n~ that there is a 
grave risk that it will only b~ ~ossibl~ to C@rry out re~e~rch in~ few 
specific are~s or th~t in ~n ittempt to eover @v@rything th~ r~sults Mill be 
superfici~l~ 
9s European cooperation in the fi~ld of biotechnology research ~nd training 
is ~ss~nti~l to build up Europ~ 0 ~ comp~titiv~ pot~nti~l~ lh@ first Europe~n 
biotechnology programM® {BEP0 which §t~nds for Biomolecul~r Engineering 
Programme) concluded in ~~rch i9S6 h~s shown how ov®r ~ period of only four 
years it ~as possibl@ to ~thieve~ great d@al despite ~n ®~trem~ly mod@st 
budget of only 15 m EtUa ~lM©st 300 proposals from the leading labor~tories 
in Europe have be®n submitted $1nte 19~2 but o~ing to the me~gr~ fin~nti~l 
resourc@s less than on~-third could b@ taken UPo In th® ar~~ of tr~ining& 84 
contracts were concluded for periods varying fro~ 6 to 24 monthso E~ch~nges 
of young scientists between leading laboratories laid the basis for what has 
rightly been c~lled ea Europe~n multidisciplin~ry tr~ining in~titut@ ~ithout 
w~lls 0 a lhe trans=nation~l char~ct~r of th® progr~mm~ ~~s furth@r und~rlin@d 
by the 63 cooperation contr~cts b~tw~en 103 ~urop@@n l~bor~toriesa Such 
cooperation Mould not h~v® b®@n possible ~ithout Europe~n coordin~tionp nor 
could the rese~rch results h~ve b~en ~thieved in such a $hort p@riodo 
10e ~swell as giving~ gr~~t d~@L of pr~ise to t~e BEP progr~Mme now 
completedp the European P~rli~~ent h~s ~lso ~oiced a numb~r of criticism~m 
The range of topics co~er~d by the BEP progr~mme ~~s e~trem~ly limited ~inc@ 
the rese~rch conc~ntr~ted on ~re~s conn~cted Mith ~griculture ~nd the food-
processing industryo ~®gret~ ~ere e~pre~sed on v~rious sides th~t industry 
had t~ken virtu~lly no p~rt ~nd that projetts Mere c~rried out only by 
universities and go~ernment l~boratorieso The limited budgetu the 
pre=competiti~e ~rea in which th~ rese~rch h~d to be Cijrried out ~nd the ~id@ 
diversity of the bioteehnolo;y industry c~n b@ tited ~s th~ re~son~ for the 
lack of particip~tion by industrya 
110 In 1985, the BEP progr~mme was followed up by the Biotechnology Action 
Programme (BAP)~ lhe budget is 55 m ECU ov~r four ye~rs~ In BAP efforts ~re 
being made to e~tend the ~re~s of r~se~rch co~er~d by BEP ~nd to tie th~m in 
better ~ith the n~@ds of Europ~~n industry ~nci ~9ricultur~o High priority h~s 
been given to cooper~tion Mith industri~L l~bor~tori~s~ New ~r~~sP ~uch ~$ 
bio-informatitsp are ~lso co~er~d to som~ @~t~nt by s~ro In order to e~pand 
internation~l e~ch~ngesp pr@f@r~nc@ has b@@n giv~n to ~roposals for training 
and research involving coop~r&tion b~tw@~n ~ numb~r of Europ~~n instituteso 
Support for the SAP progr~MM® hss been overwh@lmi~go Propos~ls for mor~ th~n 
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1 300 projects were received by the European Commissione Since here too the 
budget is extremely modest for such an ambitious programme, it has only been 
possible to approve one in seven of the projects submitted. There is a danger 
that, particularly in view of the extremely high calibre of the projects 
submitted, this may have a discouraging effect and may stifle the new spirit 
of European cooperation. In order to prevent a situation in which promising 
projects cannot be carried out, thus attacking the competitive potential of 
Europe at its roots and increasing the threat of a brain-drain to the United 
States in particular, emergency budget measures are required at least to 
double the present financial resources. 
12. An increase in financial resources is necessary to even out geographical 
disparities. Countries such as Greece, Spain and Portugal now have a raw deal 
when they could in fact make an important contribution to research and benefit 
from extension of the training and exchange programme. A larger budget is 
also necessary to finance projects resulting in socially useful products (such 
as orphan drugs) or to expand sections of the BAP such as bio-informatics 
(BICEPS), protein design and plant biochemistry. These sectors are still not 
highly developed in Europe whereas in the United States and Japan major 
efforts are being made in these promising fields. 
13. An increase in the budget is also necessary to enable greater attention 
to be paid to research into the socio-economic impact of biotechnology; a 
start has been made with a recent study by the Dublin Foundation but more 
studies and projects are reQuired. Possible topics include the regulation of 
biotechnology, risk-assessment studies, studies into the ecological effects of 
the spread of micro-organisms on a large scale, studies of pijblic attitudes 
and information, research into the effect on employment, the intellectual 
property aspects of biotechnology and the patentability of living organisms 0 
studies of the effects on the competitive position of Europe vis-a-vis the 
United States and Japan, of the advantages and disadvantages of biotechnology 
for the developing countries and of cooperation projects with non-Community 
countries, etc. Money is not only necessary to implement these projects but 
above all to establish and coordinate all these activities. As regards 
coordination, it should be pointed out that even within the institutions of 
the European Community (e.g. the various Directorates-General, such as the 
activities of DG XII/CUBE and DG XIII where a special biotechnology task force 
has also been set up), a great many more activities need to be coordinated and 
geared to one another. Coordination is extremely important in ensuring that 
information is passed on rapidly and in preventing duplication and 
fragmentation of efforts. Moreover, better coordination can reduce conflicts 
between different organizations as regards the areas within their jurisdiction 
and can helo to replace such conflicts with cooperation. 
14. The problem of European cooperation does not really acpear to Lie in 
stimulating research proposals eit'her in the area of scientific research or in 
the social and economic fields. There are plenty of ideas and there no longer r 
appears to be any reluctance to cooperate at European level, at least in the 
scientific field. Even industry is proving much more willing to give 
practical consideration to European cooperation, as shown by the setting up of 
the European Biotechnology Coordination Group CEBCG). However, the political 
will of the Member States to transfer more resources to European projects is 
still a serious stumbling block. The extent to which joint European efforts 
are reauired to meet the challenge of biotechnology is still gravely under-
estimated. Lack of harmonization in the internal market and the political 
divisions within Europe undermine its position in competition against the 
United States and Japan. However, the major changes to be expected 
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particularly in the agro=indu~trial field in the next few years require joint 
efforts. Similarly, many areas of policy connected with biotechnology, such 
as control of deliberate releases, require harmonization of national policym 
Political backing for cooperation is required if Europe is to maintain a 
strong scientific base in the coming decades and be able to establish new 
agro-industrial structures which will help to create new employment 
opportunities and to promote an acceptable environment in the broad sensem 
III~ Medium- and long-term policy recommendations for research and technology 
15. During the past two years, the Committee on Energy, Research and 
Technology has taken a number of initiatives in connection with developments 
in biotechnology and their effectsQ Since basic research and training provide 
the foundations for the advancement of biotechnology, the Committee on Energy, 
Research and Technology feels it has a special role to play in the 
coordination and monitoring of parliamentary activities connected with 
biotechnologys This report is a first step in that direction~ A conceivable 
follow-up to the report would be the setting up of an interparliamentary 
committee for biotechnologyu like that created by the Japanese Diets 
Intensive interaction and coordination of biotechnology policy between the 
various committees is likely to be of vital importance in the coming years. 
16. The following summary lists possible topics for discussion and areas of 
policy which could be put on the agenda for the Committee on Energy, Research 
and Technology in the next feM years~ 
Ca) Biotechnology should be given greater priority in the Committee on Energy, 
Research and Technology and consequently a greater share of the budget since 
biotechnology must be regarded as a crucial, ~nd key technology on which the 
future development of numerous industrial, agricultural and medical activities 
will hinge in the coming decadesm 
The results of the Biomolecular Engineering Programme (BEP) and the vast flood 
of applications for the multi-annual Biotechnology Action Programme CBAP) 
which began in 1985 demonstrate the success of incentives for joint research, 
training and development projects at European levels HoweverR more than 80% 
of the applications for the current BAP programme have already had to be 
rejected owing to lack of funds and there is a real fear that this will have 
an adverse effect on motivation and possibly escalate the brain drainQ There 
is a danger of a further nationalization of research and development instead 
of progress in the Europeanization no~ under ~ayo 
17s Cb) An increase in the BAP budget only makes sense if clearer priorities 
can be established than has hitherto been the case~ This requires further 
coordination between the Member States~ However, not everything has to be 
financed at European level, only those aspects of research, development and 
possible applications which cannot be carried out by individual Member States 
on economic grounds, or where there is insufficient manpower and know-how at 
national levelm Greater consideration should also be given to training, 
particularly for the less-developed countries in the Community such as Greece, 
Spain, Portugal and Ireland so as to prevent biotechnology undermining 
integrationo Moreover, with the ~id of biotechnology these countries have the 
potential to become the 'California of Europe 9 in agricultural terms. It 
should be seen, in conjunction with the Committee on Regional Policy, how such 
a goal could be achievedo 
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18. Cc) Top priority should be given to research and development projects 
which contribute to socially useful products. These might be in the area of 
•orphan drugs' which have extremely high development costs and low profits. 
It should be seen how the Science, Technology and Development (STD) programme 
can be coordinated with the BAP programme in the area of medical biotechnology 
(tropical sicknesses, vaccines). In the area of environmental biotechnology 
(e.g. degradation of toxic substances), a more detailed study should be made, 
in conjuction with the Committee on the Environment, of how sections of the 
SAP programme or its suceessor can be developed in this direction. 
Coordination between BAP and the DG XI environmental programmes should also be 
encouraged. In the area of Local, small-scale energy production, particularl) 
for backward rural areas and for developing countries, projects should be set 
up in cooperation with the Committee on Regional Policy and the Committee on 
Development and Cooperation. 
19. Cd) Developments in the area of bioinformatics, as announced in the 
provisional proposals for the BICEPS programme, should be expanded to ensure 
that Eurooe does not lose ground to US and Japanese competition in the border 
area between biotechnology and informatics. Bioinformatics is a vital link in 
the development of biotechnology and for both informatics and health care. 
Bioinformatics is extremely important in passing on know-how - even at 
secondary school level. Access to computerized data banks can forge links 
between university institutions, schools and industrial laboratories. A great 
deal of thought should also be given to training in the area of bioinformatics 
which is likely to provide skilled job opportunities. One could mention here 
the development of artificial intelligence, expert systems, advanced computer 
software, biochips, data banks, etc. Close cooperation between BICEPS and 
DG XIII's task force for biotechnology should be encouraged so as to make the 
best possible use of the available resources. In the area of data banks and 
the dissemination of high Quality information in particular, there should be a 
clear division of tasks between DG XII and DG XIII. 
20. Ce) It is important to ensure that the BAP programme continues to act as 
a catalyst. The Commission should not take on an entrepreneurial role and 
with it the risks run by industry. It would therefore appear to be advisable 
for funds not to be allocated direct to firms but rather to joint ventures 
between university researchers and industrial Laboratories to ensure continued 
consolidation of the research base and to give a greater guarantee of public 
access to the research findings. On the last point - access to the results of 
research funded partly by public bodies - continuous monitoring will be 
reauired in the next few years. 
21. (f) In the short term, it is important to clarify the potential damaging 
effects of experiments in the environment with genetically engineered and 
exotic organisms. In this area, the Committee on Energy should cooperate 
closely with the Committee on the Environment, Public Health and Consumer 
Protection, the Committee on Legal Affairs and Citizens' Rights and BRIC 
(Biotechnology Regulation Interservice Committee) of the European Commission 
as well as with the Information Service. The planned European Office for 
Technology Assessment will provide a vital link in this chain. In its work, 
the European OTA should give priority to providing unbiased information on 
biotechnology for the general public since it has emerged that the further 
development of biotechnology will be determined largely by information 
campaigns and the role of public opinion. 
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Kees van den Doel and Gerd Junnep Product substitution through 
biotechnology: Impact on international relations, a report published as 
part of a research project financed by the Community into the social and 
economic effects of biotechnology and coordinated by the European 
Foundation for the Improvement of Living and Working Conditions, Dublin, 
May 1986. See also Kees van den Doel and Gerd Junne, 'Product 
substitution through biotechnology~ impact on the Third World', in: 
Trends in Biotechnology, April 1986, Po 88-900 
See footnote Sm The American Office of Technology Assessment calculates 
that the number of farmers in the United States will fall by half to 1.2 
million in about a decade. Only 50 OOO of these farms will provide 75% 
of total agricultural outputs As a result, traditional family farms will 
disappear and only part-time farmers with small plots and extremely large 
farms will remaino 
Commission of the European Communities, BRIC, The Commission's approach 
to the regulation of biotechnology, Brussels, February 1986; Commission 
of the European Communities, BRIC, The European Community, and the 
regulation of biotechnology: an inventory, Brussels, March 1986; 
Annemieke Roobeek, 'Biotechnology and regulation: different perspectives 
in the United States and the European Community•, in: Trends in 
Biotechnolog1,u ~pril 19~6g ~Po 15=18 
Guiseppe L~nz~v~cehi~p lh~ i~p~~t ,of biotechnology on Living and working 
conditionsp ~OM~o ~pril 19860 l~is report appe~red as part of th~ 
rese~rch project fin~nced by th~ Community into the social and economic 
imp~ct of biot®chnology ~~d coordinat@ci by th~ European foundation for 
the lmpro~@ment ©f livi~g ~nd ijorkin; Co~ditionsp ~ublino 
Jo$eph Go Perpich§ B~ f®der~l Str~tegy for Int~rnation~l Industrial 
Comp~titivene~~au i~g BI@ITEt~NOlOGVp Volo 4p J~ne 1986, PPo 522-525s 
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MOTIO~ fOR A ~ESOLUT!O~ 
DOCUMENT B 2=519/§5 
tabled by Mr ~OU~p ~r M~~L~!~p ~r C~~!GNO~§ ~r fXTISI~O~S 1nd ~r L~LO~ 
on beh~lf of the Group of th~ Europ®~n ~~motr~tit ~lli~nce 
pursu~nt to ~ule 41 of th~ ~ul~s of Proc~dur~ 
on res~~rth in th~ field of biot~chnolo;y 
A" having regard to the epplic®tion of new technology to living organ;sms and 
v~rious m~t~ri~l~ 0 ~noMn ~s biot@thnology0 
B~ having reg~rd to th~ gro~ing ~ncl truciil import~nce of the biot~chnology 
sector in th~ futur®
0 
on~ ~~r Mit~ d~t~ prot~ssing6 micro=@l~ctronics0 
ettop 
Co having reg~rd to the ~id~ranging effects of research in this area on such 
diff~r~nt s@ctors as 
~ agri=foodstuffs 9 he@lth {~ntibiotit~o More r~liabl@ ~nd n@~ v~ccines 9 substitute 
horrnon~s)p ~ ~n@rgy Cobt~ining $ynth~tic p@trol froM ~eg~t~bl~ matter) 
o th~mical~ C~nrithin~ l~M-gr~de ore~)R 
Do where~Sp ~ft@r 1990~ it is ~stimat~d th~t mor~ thin 250 billion fr~ncs 
~ill b~ invest~d in biot@thnologic~l r~$~~rch ~~try ye~r~ 
F. having reg~rd to the efforts made in the field of research by the FRG and 
fr~nce in ord@r to ~~in~ foothold in thi~ mark~t (2o5 billion ff h~ve 
b~en invest@d 1n biot@t~nologic~l r~s~©rth i~ fr~nt~>u 
1" Considers it vital that the Community snd ~ember States take coordinated 
~ction in thi~ ~r@ap pirticularly in order to~ 
Q t~ke up th~ ~m~rican ~nd J~p~nese ch~ll@n@eo 
o occupy what isR in vi@w of their int~lleetu~lR technologic~l and 
fin~nci~l c~p~citiesu th~ir ri~htful plic~ in this seetoru 
s ~void overl@P ~nd fin~nci~l loss9 ~rising from th~ eomp~rtm~ntaliz~tion ~ of the public and priv~t~ ffi~r~~t$ in th~ Communityo 
, 
2o Consid~rs th~ dr~wing up of~ l~rge=st@le Europe~n biotechnology programm~ 
~long the lin~s oft~@ ESPRI1 programMep to b~ urgent; 
3~ Considers th~t the tommunity mu~t not l~g b~~ind in thi~ very promising 
sectoru ~sit did in d~t~ proc~~~ingp micro=®l@ttronics 6 etcc; 
4o Points out th~t th@ biot~thnology $~ttor op~ns up ~r@~t prosp~tt~ in terms 
of jobs 0 
So Believes more t~~n ~~@r that h~r~ ~sin oth~r activiti~sp th~ need for 
Community ~ction i~ closely linked to th@ p~r~ll@l creation of~ huge 
intern~l m~rk@tp 
6. Instructs it President to forMsrd this resolution to the Com~ission of the 
European Communities and the touncilQ 
= 22 = 
MOTION FOR A RESOLUTION 
DOCUMENT B 2-1087/85 
tabled by Mr TOLMAN, chairman and Mr EYRAUD, first vice-chairman, 
on behalf of the Committee on Agriculture, Fisheries and food 
pursuant to Rule 47 of the Rules of Procedure 
on the use of agricultural products in biotechnology 
The European Parliament, 
ANNEX 2 
A. having regard to the need to step up efforts to increase outlets for 
agricultural products other than for use as food, 
B. having regard to the Community's efforts to develop biotechnology in the 
very near future, 
C. having regard to the excellent opportunities for using a large number of 
agricultural products in biotechnology, 
D~ whereas the use of agricultual products in biotechnology may have 
conseauences for the future of European agriculture, 
Eu whereas biotechnology has been included in the EUREKA project, 
1. Calls on the Commission to submit a study on the impact of the use of 
biotechnology on European agriculture; 
2a Invites its competent committee to draw up a report on the subject; 
3Q Instructs its President to forward this resolution to the President of the 
Council. 
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MOTION FOR A RESOLUTION 
DOCUMENT B 2-1162/85 
tabled by Mr PEARCE 
pursuant to Rule 47 of the Rules of Procedure 
on developments in the manufacture of hormones 
The European Parliament, 
ANNEX 3 
A. having regard to the motion for a resolution on dwarf-tossing tabled on 
29 August 1985 by Mrs SQuarcialupi (Doc. B 2-784/85), 
B. being led to believe that developments in the manufacture of hormones may 
soon provide new means of treating dwarfism at an early stage, 
1. Urges the Commission of the European Communities to produce a brief report 
on research in the Community into this matter so that application of 
public and private funds to such research may be carried out in the 
fullest knowledge of current developments and may come speedily to a 
successful conclusion; 
2. Instructs its President to forward this resolution to the Commission of 
the European Communities. 
WG(VS1)/3858E - 24 - PE 105.423/fin./Ann.3 
OPINION 
(Rule 101 of the Rules of Procedure) 
OF THE COMMITTEE ON AGRICULTURE, FISHERIES AND FOOD 
Draftsman ~ Mr T. TOLMAN 
At its meeting of 5 February 1986, the Committee on Agriculture, Fisheries and 
food appointed Mr Graefe zu Baringdorf draftsman. 
The committee considered the draft opinion at its meetings of 2/3 April and 
22/23 April 1986 and adopted the conclusions thereof at the latter meeting by 
19 votes to 6 with 2 abstentions. 
In the light of the result of the vote, the draftsman, 
Mr Graefe zu Baringdorf9 stood down in favour of the committee chairman, 
Mr Teun Tolmana 
The following took part in the vote: 
Mr TOLMAN, chairman and draftsman; Mr EYRAUD, Mr GRAEFE ZU BARINGDORF, 
Mr MOUCHEL, vice-chairmen; Mr ABENS (deputizing for Mr Woltjer), Mr ADAMOU, 
Mrs ANDRE (deputizing for Mr Nielsen), Mr BARRETT (deputizing for 
Mr MacSharry), Mr BORGO, Mr CHIABRANDO (deputizing for Mr F. Pisani), 
Mr CLINTON, Mr DEBATISSE, Mr ELLES (deputizing for Mr Battersby), Mr FILINIS 
(deputizing for Mr Gatti), Mr GARCIA, Mr MAHER, Mr MARCK, Mrs MARTIN, 
Mr MERTENS, Mr MORR!Sp Mr MUHLEN (deputizing for Mr frQh), Mr NAVARRO VELASCO, 
Sir Henry PLUMB (deputizing for Mr Simmonds), Mr PRANCHERE, Mr PROVAN, 
Mr RAFTERY (deputizing for Mr Dalsass) and Mr ROSSI. 
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The tommittee on ~gricultur~ 0 fish~ri@s and food r~Qu~~ts th~ ComMitte@ on 
Energyp ~~s~~rch ~nd r~ehnology to t~ke ~ccount of th~ folloMing conclusions 
~hen it dr~M~ up its report~ 
The tommitt@e on ~gri~~ltur~p ~i~~eri@s ~nd ~oodp 
1o ~pplauds the eompr~h~n~,~~ ~nd lucid appro~th adopt@d by th~ rapporteur0 
Mrs Vi~hoffu to th® subj@tt of biotechnology; 
2o In vi@M of the ~ot@nti~L imp~et of biotechnology on food produttion ~nd 
processing 0 decides to dr~~ up a ~ep~r~te o~n=initi~tiv® r~port on 
biotechnology in th@ ~~rieultur~l $~ttor; 
3o The uses of g@netie M@nipul~tion ~nd pl~nt tissu~ tulture t~c~niques will 
greatly ~ctel~r~t~ ~ti~ntists 0 ~bility to g@n~r~t@ More g~n@tit div~rsity 
whichp in turnp will off®r more opportuniti®s to produc@ v~ri~ties ~uitible 
for~ wider r~ng® of soil~ ~nd eliM~t~sm This ~ill @lso off~r incre~sed 
opportuniti®~ to ~@lett for thar~tteri~tics suth ~s dis®~s~ ~nd pest 
resistant~u high@r prot~in l®~~l~ with b@tt®r milling ~nd b~king ~u~lity~ in 
th~ t~se of ~h~~tp ~nd loM®r protein l®v~ls with high@r st@rch content for 
malting b~rl~YSu @tta 
In the short and m@dium t~rM 0 g~n®tic ~ngin®ering of ~hi~obia m~y incr~ase the 
efficiency of nitro~®n fi~~tions in l@gum@so In th~ longer t~rmu it may be 
possibl~R using g@n~tie M~nipul~tion of pl~nts ~nd ~~n@tic engineering of 
bact~ri~u to ®n~bl~ plants of t~e Gramine~e f~mily& such ~s cere~ls ~nd grassp 
to fi~ ~tmosph~ric nitrog~n; 
4o D~velopm@nts in r®producti~~ physiology (p~rticularly in th~ c~s~ of 
c~ttle and she@p) such ~s ~rtifieial twinning§ non=~urgie~l tr~nsfer of 
fertili~@d ovaP pr~d@t~rmin~tion of s~~c ~tCac ~ill h®lp to enh~nc~ g@netit 
merit 0 incre~s~ f~cunciity ~nci r~duc~ prod~ttion costs0 
5@ While r®cogni2in@ th~t biot@chnology ~~Y r®duc® th~ ne~d for fungicidesp 
b~ctericides 0 p@stiticl@s ~~d nitrogenou~ f~rtili~®r by producing crops ~hich 
are more r~sist~nt to di~~~se ~nd more effici~nt in ~itro~en fi~ation from the 
atmospher~9 we mu~t al~o r®cognii® th~t g@n~tit m~nipul~tion ~nd plant tissue 
culture m~y al~o giv@ crop~ mor@ r@~ist~ne~ to ch@mitil~ $Uth ~s M@~d~iller$; 
60 Dev~lopments of biot~c~nolo~y in th~ Community ~ill r~~uir@ c~rt~in 
conditions to b@ metp intluding 
(a) th® l~ying do~n of Europ@~n ~~fety rul~s and st~nd~rds for produets 
deriv~d from b1ot~thnologyi 
(b) the provision of ~~tr~ r~$earch fund$p and th@ pl~cing ~t th~ disposal of 
r~se~rchersp p~rticul~rly in th~ field of g~netic~0 of inform~tion 
technologie~ g~~red to the n~@ds of biot~thnologyp both for the collection 
of dat~ (las~rsu ~=r~ysp en~yffi~tic el@ctrod~s ~ncl re~ote sensing by 
s~tellite for ~gritultur~) ~nd for their stor~g~ (d~t~ b~n~s for 
biotechnic~l researthp ~teQ)O It isp th®r~for~P v~ry import~nt to d~velop 
the field of ~pplie~tio~ oft~~ ESP~I1 progr~M~® in thes~ ~r~~s of 
b1o=i~form~tics 9 ot~@r~is~ th@r@ is~ d@ng@r t~~t the inform~tion networks 
developed will b@ 1~t0Mpit1bl® ~ith ~~t~ oth®r a~d th~t t~e d~p@nclenc~ on 
ce~tres outsid® th@ Coffimunityp ®~p~cially in th@ ~S ~nd J1pinp will grow; 
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Cc) the dev~lopm~nt of signific~nt @~th~ng~ progr~~m~~P involving not only 
~~chang~~ of re~e~rth~r~ b@t~e~n univ~rsitie$ ~nd r~$e~rch institut@s b~t 
also e~ch~nges with ~gri=food$tuffs indu~tri~~ ~nd ph~rm~c®~tical 
comp~nies ~hieh ~lso m~ke ~n i~~ort~nt tontrib~tion to rese~rch in this 
field; 
(d) measures to provide th® Community Mith mor~ fl~~ible and more eff@ctive 
protection for inv~ntions (p~riods of grac~ of si~ months to~ ye~r for a 
pate~t applic~tion to b@ lodged ~fter disclosur~ of th~ inventionu 
~dmi~sibility of p~t~nt ~ppli~~tions for mitro=org~ni$M~ per s~0 possible 
~ntension of th~ length of ~~t~ntSp @tto)o 
The flow of in~estment for inno~~tion depends to~ l~rge @~t®nt on the 
effectiveness of th@ prot~ction off@r@ci by p~t®nts and u~on the m@ans 
av~ilabl~ to ~omb~t infring®m@nt$; 
1e ~ecogni2~s th~t biot~thnology tould ~n~bl~ th~ ~gri=foodstuff§ and oth~r 
industri®s to us~ subst~nti~l ~u~ntiti~s of ~gricultural ~rodue~ ~nd also 
enable some of th® @nvironm@nt~lly ~a~ardous by=produetsp such ~s ~hey ~nd 
~nim~l w~stesp to be eonv~rt@ci to us~ful ~nd ~~luabl~ products such~~ potable 
alcohol @nd methin~ g~sJ 
So The suct@ss of bioteehnologie~l industries ~hich U$e r~w rn~t~ri~ls from 
agriculture (eogG the drin~s industry) d~pend~P ~mongst oth~r thingsp upon a 
reli~ble ~upply of r~w miteri~ls of th@ torrett Quality ~nd ~t pric~s 
satisf~ctory to both produc@rs and processorsc 
= 21 = 
OPINION 
(Rule 102 of the Rules of Procedure) 
Draftsman: Mr RAFTERY 
On 29 January 1986, the Committee on Economic and Monetary Affairs and 
Industrial Policy appointed Mr Raftery draftsman. 
The committee considered the draft opinion at its meetings of 19-21 March 1986 
and 21-23 May 1986 and at the latter meeting adopted it by 21 votes to O with 
2 abstentions. 
The following took part in the vote: Mr SEAL, chairman; Mr BEAZLEY, 
vice-chairman; Mr RAFTERY, draftsman; Mr ALVAREZ DE EULATE, Mr BAILLOT, 
Mr BEIROCO, Mr BRITO APOLONIA (deputizing for Mr Filinis), Mr BUENO VICENTE, 
Mr CASSIDY, Mr GARCIA PAGAN, Mr GASOLIBA i BOHM, Mr GAUTIER, Mr HERMAN, 
Mr KILBY (deputizing for Mr DE FERRANTI), Mr LATAILLADE, Mr MARQUES MENDES, 
Mrs TOVE NIELSEN, Mr PATTERSON, Mr PEGADO LIZ (deputizing for Mr Mancel), 
Mr ROSA (deputizing for Mr Rogalla) and Mr STAUFFENBERG (deputizing for 
Mr von Wogau). 
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I. INTRODUCTION 
1. The importance of biotechnology 
Recent progress in the life sciences has provided us with an increasingly 
extensive knowledge of biological structures and functionsm The new 
biotechnologies, the science of the use of biological processes, which have 
resulted from these developments will lead to an ever-increasing number of 
applications over a wide range of different sectors of economic activity. 
In agriculture, biotechnology will make it possible, through the application 
of new genetic technologies, to improve existing species and create new ones 
with quicker reproduction potential. This will result in improved yields and 
reduced costs, mainly as a result of lower consumption of fertilizers and 
pesticides. The large-scale production of new enriched protein foodstuffs can 
also be envisagedw 
Most chemical products manufactured in the world derive from hydrocarbons. 
However, thanks to biotechnology, it is possible to develop new chemical raw 
materials (micro-organisms, intensive culture of algae, use of lineocellulose). 
fermentation technology and enzyme technology are also opening up countless 
possibilities in the chemical sector~ using raw materials derived from 
agricultureo New possibilities are also being opened up for agriculture, 
particularly through the development of the agri-foodstuffs industries. 
Biomedical technology has already made great strides, offering prospects for 
significant progress in the field of diagnosis (monoclonal antibodies), the 
inventory of human proteins and the production of vaccines and hormones by 
means of genetic engineering - progress which will reduce the cost of health 
expenditure while improving the effectiveness of treatment.· The second 
pharmaceutical revolution is opening up prospects for significant progress. 
The annual savings which could be achieved from only a 1% reduction in health 
expenditure in the Member States would be substantial, not to mention the 
benefits produced by improved medicines derived from biotechnology. 
Finally, without mentioning the possibilities of the biological processing of 
minerals (lixiviation) or the recycling of waste, biotechnology applied to 
biomass also offers prospects for alternative sources of energy. 
Given that 40% of manufacturing production in the industrialized countries is 
already biological in nature and origin, economists believe that biotechnology 
will be a driving force for innovation leading to the beginning of a long new 
cycle which will sustain the Western economies. 
2o The characteristics of biotechnology 
Biotechnologies also have specific characteristics. They involve numerous 
scientific disciplines and require considerable back-up in terms of 
informaticsa Their applications cover a wide range of products or services 
and overlaps and conflicts can therefore be expected both between different 
sectors and different countries. Finally, they will continue to require 
substantial financial resources. The range and scale of the economic, social 
and ecological impact of biotechnology inevitably make it an international 
undertaking, reauiring the introduction of a Community strategy as a matter of 
the utmost urgency, especially in view of the Lead already enjoyed by the 
United States and Japan in this field. 
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The conclusions which follow reflect the priorities which should be set fro~ 
the economic point of view in order to create a climate favourable to a 
successful Community strategy for biotechnology~ 
IIc CONCLUSIONS 
In conclusion1 the Committee on Economic ~nd ~onetary Affairs and Industrial 
Policy believes that 
1. Biotechnology is a source of new growth, particularly in the agri-
foodstuffs~ chemical and pharmaceutical sectors and it can also contribute to 
the process of reforming the common agricultural policy by offering Commu~ity 
agriculture new possibilities, it can help ~ith reducing health ~xpenditure 0 
the decentralization and convergence of economic activityu the cl~velopment of 
SMU, especially those with capacity for innovstion, and increasing the 
Community's energy independence§ though it must be stressed that bio-ethanol 
has no economic justification in the curr~nt state of the world energy m~rk~t; 
2e The range of the possible applications of biotechnology§ p~rticularly in 
the sectors of ~griculture, foodstuffsp medicine and pharmaceuticals, energy 
and the environment, together with the international and interdisciplinary 
nature of the research and the scale of the resources reQuiredp make it a 
vital undertaking for the economic future of the Communitya Hence the need 
for an extensive Community strategy and programme for biotechnologyp taking 
account also of the lead enjoyed by the United States and Japan in these 
sectors; 
3m In this respectu it is essential to pursue the programmes undertaken by 
the Commission, particularly the research action programme in the field of 
biotechnology (1985-1989 BAP) adopted by the Council on 12 M~rch 19850 
Nevertheless, this programme, which was devised at the precompetitive stage 
and on the basis of shared=expenditure contracts, seems too restricted both in 
its field of application and the resources at its disposal (55 m ECU)s 
Conseauently, too many projects have been rejected and abandoned for L~ck of 
finance§ despite their undoubted value; 
4s The Commission should therefore consider drawing up a new research 
programme in the field of biotechnologye In shortp it is vital for the Member 
States to coordinate and develop their research activities on a European sc~le 
in the field of biotechnology, so as to avoid unnecessary duplic~tion of 
research and assemble the concentration of transn~tional resources without 
which our research cannot achieve genuine success, given the need for an 
interdisciplinary approach ~nd the cost of research in this sectoro 
Collaboration and synergy between national programmes and activities should be 
promoted both through implementation of Commission research contracts and 
through concerted action; 
5e Consideration must be given, as~ matter of urgency, to the possibiliti~s 
for breeding or switching cultivation to crops with new properties and 
potential uses outside the foodstuffs sectoru to enable farmers to react to 
market developments by making the appropriate modifie~tions to their 
production ranges; 
6m The development of biotechnology in the Community will require numerous 
conditions to be met in order to create a favourable climate, including~ 
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Ca) the laying down of European safety rules and standards for products 
derived from biotechnology (recombinant DNA technologies, for example). 
The Commission is requested to provide Parliament's appropriate committees 
with immediate information on the work being carried out in the OECD; 
Cb) placing at the disposal of researchers, particularly in the field of 
genetics, information technologies geared to the needs of biotechnology, 
both for the collection of data (Lasers, X-rays, enzymatic electrodes, 
remote-sensing by satellite for agriculture) and for their storage (data 
banks for biotic research, genetics and macromolecules and for cells, 
plants and animal tissues)o It is therefore vital to develop the field of 
application of the ESPRIT programme in these areas Cbio-informatics), 
otherwise there is a danger that the information networks developed will 
be incompatible with each other and that dependence on centres of 
expertise outside the Community will grow; 
Cc) providing the pharmaceutical and agri-foodstuffs industries in particular 
with a satisfactory supply of raw materials; 
(d) a significant increase in European exchange programmes, involving 
exchanges of researchers and teachers between university institutes and 
large pharmac0utical and agri-foodstuffs companies, which also make a 
substantial contribution to research in this field; 
(e) measures to provide the Community with more flexible and more effective 
protection for inventions in the field of biotechnology, as regards patent 
law, the law on the protection of new varieties of live plants and other 
legal provisions (periods of grace of six months to a year making it 
possible for a patent application to be Lodged after disclosure of the 
invention, admissibility of patent applications for micro-organisms per 
se; possible extension of the length of patents and speeding up of 
procedures). These problems must be resolved because the flow of 
investment depends to a large extent on the quality and effectiveness of 
the protection offered by patents and on the means available to combat 
infringementsm The Commission should encourage the necessary cooperation 
within the OECD; 
7m Given the cost of research, which can often be very long and speculative, 
the success of a Community strategy for biotechnology depends in the final 
analysis on an appreciable increase in Community finance for research, which 
is reauired to play an important role as a stimulus, together with the kind of 
financial project development (risk capital) which is sadly lacking in the 
Community a 
8~ It is important also to promote research programmes to investigate the 
socio-economic implications of the application of genetic engineering and 
biotechnology. 
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1 ii 
OPINION 
of the Committee on legal Affairs and Citizens' Rights 
At its meeting of 27 February 1986 the Committee on Legal Affairs and 
Citizens 9 Rights appointed Mr A.Ea Turner draftsman. 
The committee considered the draft opinion at its meeting of 18-19 June 1986 
and adopted it unanimouslys 
The following took part in the vote: Mrs VAYSSADE, chairman; Mr DONNEZ, 
vice-chairman; Mr TURNER, draftsman; Mr ALBER, Mrs BONINO, Mr CASINI, 
Mr GARCIA AMIGO, Mr HOON, Mr LUCAS PIREZ, Mr MEGAHY, Mr PEGADO LIZ, Mr PRICE, 
Mr PROUT, Mr ROTHLEY and Mr VERDE I ALDEA. 
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INTRODUCTION 
1s This opinion is directed to the various legal aspects on development of 
biotechnology in Europe, from the time of conception and invention through 
research, development, commercial exploitation and, finallyp exporting~ 
PATENTING PROBLEMS 
2a It is necessary in patent Law to provide a description of the nature of 
the invention sufficiently clear to enable the public to carry out the 
invention. The reason for this is that the consideration for protection is 
knowledge given to the public. In the case of micro-organisms, it is 
impossible at the present time to define in words a micro-organism 
sufficiently clearly to be reproduced by an expert. Thus it is necessary to 
deposit examples of micro-organisms. The problem with this however~ is that a 
member of the public could then take the micro-organism from the deposit and 
reproduce it without carrying out any original work of his ownm Thus a 
deposit goes much further than is required in patent Law~ 
Identification of micro-organisms for patent orotection 
3. In the United States and Japan deposited micro~organisms cannot be 
obtained by the public until after grant of the patenta Under the Munich 
Patent Convention, such deposits would be available immediately, that is 
before grant, and thus the public would be enabled to take the invention 
before the applicant had received protection for it. It would be difficult at 
the present time to amend the Munich Patent Convention. The European Patent 
Office has proposed a system whereby an independent expert can be reQuested by 
members of the public to examine a deposited micro-organism without allo~ing 
it into their handsc It would be a condition of independent inspection that 
it should be for the purpose solely of providing a proper identity of the 
micro-organism and sufficient information to repeat the invention as required 
by patent lawd This appears to be a very practical method of delaying with 
the problemm However, not all Member States of the Convention have accepted 
the conceptD It wouldp therefore, be desirable for all Member States to agree 
in common that they will accept this procedurec Although it is very 
impractical to amend the Munich Convention, perhaps at a later stage the 
American and Japanese provision whereby deposits are not available until after 
grant could be adopted. 
4o Even after grant, the micro-organism deposited could be misused by members 
of the public who could use the exemplification to reproduce micro-organisms 
themselvesm It has therefore been proposed that there should be restrictions 
on the use of such deposits preventing their transfer to other partiesp and 
preventing their removal from the country of deposit. However, it would 
appear that the best solution would be to maintain the use of the independent 
expert after grant as well as before grant. 
Protection of plants and animals 
Sa Under existing patent Law, plants, animals and biological processes for 
their reproduction are excluded from patent protection: however, there is 
protection for plant materials in various national Laws on plant breeders' 
rightso The latter are Limited in that only the propagative material of a 
plant is protected: this means that one can sell the produce of a protected 
plant. Until recently, the principle thus set out had been accepted 
generally; however, in the United States very recently case law has held that 
plants can be protected by patent right as well~ This~ of course, is a very 
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prob~bly b@st to l~~ve th~ syst®~ ~~ it isa ~th~r ~~thods should be employed 
to ~nocour@ge univ~r~ity tirtl@~ to build up tlO$~ li~ks ~ith industryp ~nd 
this c~n prob~bly b~st b~ cl©~@ by ~nt©ur~gin~ uni~@r$iti@$ t~@~s®l~®s to tak~ 
out p@lt@nt ~ o 
9o A good d®al of work has been done in Europe 9 the United St~te~ ~nd Japan 
on the ~uestion of r@~ul@tion fort~@ s~fety of biot@ehnologital processes and 
produet~o 1her@ ~pp@~rs to be developing g@n~r~l con~ensus th~t biotechnology 
should not be treated a~ 1 different problem in kind from other que~tions of 
saf~ty of hum~n~ 9 anim@l~p indu~tri~l prot@~~e$p ~gritultur~ ~nd th~ 
~nvironmento !t is pointed out th~t m~ny bioteehnologie~l prot@sses (most 
not~bl@ in ferment~tion) had been ~~ed for very m~ny y@~rs and furthermore 
that neH ~tr~in~ h~v@ b®®n produced in ~nim~L~ and pl~nts by ~~P~~z~rd methods 
of breeding for m~ny y~~rs ~nd without ~p~ti~L provisions for safetvo This 
~~ner~l tonclu~ion ~P~®~r~ to b~ corretto furt~@rmor~P it i~ ele~r that there 
is not ~uffiti@nt knowl@d~e ~t the pr~$~nt st~g~ ~~ to how the biotechnology 
industries will develop to be 1ble to Lay down general provisions eau~lly 
applic~bl~ ~nd ~uit~ble to ~ll d@~@lopm~nt~m It ~l~o ~pp~~rsp ~mongst 
inter~~t@d circl~~p th~t t~i~ h~$ l~d to th~ b~li@f t~at ~ specific 
c~se=by-c~s® proc@dur@ ~hould b@ ~ppli@d to th® r~gul~tion for ~~f~ty and the 
~n~ironm~nt for pupo$eS of biot~thnologyo for in~t~nt~p on@ ea~~ ~ill involve 
org~nism~ c~p~ble of ~~ry f~~t r@produttionp ~h@r@~~ oth®r$ will involve 
or~~ni~ms Mith ~~ry $lo~ r@pro~u~ti©no Thi$ ©O~tlu~ion ~lso ~pp@~rs to be 
reaisonaibl~.,, 
10a Thus there i~ no n@@d or d~~ir~bility for pref@renti~l tr~~t~ent to 
bioteehnologyp th~t is in th® form of cliff~r~nt principl~~ to b~ applied to 
biot~thnological prot@~se~ ~nd product~ from oth®r foodstuff~§ ph~rm~c~uticalsp 
~nim~l foodstuffsp ~gritultur~l r@gul~tions or en~iron~~nt~l measur~s ~ the 
requirement is for ~n ~ppr~ci~tion th~t wh@~ st~nd~rds ~r~ b@ing ~pplied and 
proc~dur~s follo~®d th@ ~p~ei~l f~~tur®s of biot@thnolo@y ~h~ll b~ fully t~ken 
into account i~ th~ m~nn®r ~~tout b~low0 lhus to giv@ ~n ~~impl~P clirettives 
or natio~~l l~Ms on ~gro=eh@~ic~l~ would b~ ~ppli~d simil~rly to 
biotechnologie~L as to other m~t@ri~l~u Mith th~ pro~i~o th~t M~@re there h~ve 
be~n low limit ~~~mptions permitting ~M~ll=~t~l~ fi~ld trial~u outside th~ 
safety labor~tory conditionsp t~~~® e~~mptions ~ould not apply in th@ c~se of 
biotechnologic~L m~teri~l~ 0 b~c~u~~ of th~ n®~d to ~n$ur~ t~~t th~r~ 1s no 
esc~p~ of r@producable ~~t®ri~l into the environm@nto furth~rmorep more 
res~~rch is re~uir~d into the condition~ of r~l~@Se ~nd b@h~viour of r~NA 
org~nisMs when r@le~sedQ 
11s It is desir~bl® 0 in the fir~t pl~tep th~t d@v@lopm~nts in the United 
~t~tesp J~p~n ~nd Europe should go ~long parall@l lin~s with ~pplic~tion of 
th@ same gen~r~l principle~ ~nd proc@dure~ ~h®r@ po~sibl~o Xt 1$ @~c®@clingly 
important th~t in Europe it~~lf& ther@ should b@ ~ tommon s®t of r~quir~ments 
@nd procedur®sp th~t th@y $houlcl b@ appli@d by ~uthoritiis in th~ ~®~ber 
St~tes under Community dir®etiv@~ ~h@r~ n®~@$$~ryR ~ncl th~t ther~ $~ould be 
mutual recognition of ton~@nt~ giv®n by on® M@@ber ~t~t~ in the oth@rsQ ~ll 
these obj@ctives @re in f~tt b~ing r®eogni~®d insofar~~ bodi~sp such as the 
OEC~p are bringing tog~ther informed @nd interested opinions ~nd th@r~ 1$ ~ 
very large me~sur®$ of ~greem@nto C~BE1p ~~xc2 ~nd ssc3 in th® 
Commission ~re much involv®d in these objeetiv~~o 
icuBE ~ Cone~rt~tion Unit on Biotechnology in Europe 
2e~IC ~ Biot~thnology ~egul~tion lnterde~~rtm@nt~l Committ@e 
3ssc = Biotet~nology St~@ring Committee 
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probably b@~t to le~v® th® $yst®m as it iso Oth~r m~thods should be employed 
to enoeour@ge university circl~~ to build up tlO$@ links Mith i~dustryu ind 
this c~n prob~bly b~st b, don@ by ~~t©ur~gi~g u~iv@r~iti@s t~®ffi$~lv@s to take 
out pit@nt~a 
Introduetion 
9o A good deal of work has been done in Europeg the United St~tes and Japan 
on the que~tion of r®gul@tion forth~ ~~f~ty of biot®thnolo~ital processes and 
produtt~o Yher® ~p~e~r$ to b@ clev~lo~ing @®n®r~l eonsen~us th~t biotechnology 
should not be treated as~ different probleffi in kind from other que$tions of 
safety of hum~n~p ~nim~l~p indu~tri@l proe@~~~Sp ~griculture ~nd the 
environm®nto It i~ point@d out t~~t M~ny biot®chnolo~ieal prot@sses (most 
not~bL@ in ferm@nt~tion) h~d b~~n u~ed for ~~ry m~ny y@~r~ ~nd furthermore 
th~t n®M str~in$ h~V® b@®n produt@d in anim~l~ ~ncl pl~nt$ by h~~~~z~rd methods 
of bre~ding for m~ny y@~r~ ~nd Mithout ~~@ti~l provi~ions for ~afetyo This 
g@n~r~l concLu~ion ~PP®~r$ to b@ corr®cto furt~@rmor@p it is cle~r that there 
is not ~uffiti~nt ~no~l@dg@ ~t t~® pr~~~nt $t~g~ a~ to ho~ th~ biotechnology 
industrie~ 8ill d@v®Lop to be ~bl~ to l@Y down g~n~r~l provision~ ~~u~lly 
applic~bl~ ~nd suit~bl@ to ~ll d~~@lopm®nt~m It ~L~o ~pp~ar$p ~mon9st 
int~r@st@d tirtl®~p th~t t~is h~~ l®d to th~ b~li~f th~t ~ $pet1fic 
c~se=by=t~s® proc~dur@ ~hould b@ ~ppli®d to th® r~@ul~tion for ~~f~ty ~~d the 
~n~ironm@nt for pupo~e~ of biot~thnologvo for inst~nt~p on~ e~se will involve 
org~~ism~ t~p~bl~ of ~@ry f~~t r®produttionp ~~®r@~~ oth~rs will involve 
organi§MS with ~~ry ~lo~ r@prod~tt~@no T~i~ ~©ntlu~ion ~lso ~~~@~r~ to be 
r~@son~bl~~ 
100 Thu~ th~re i~ no n@ed or desir~bility for pr~f~renti~l treatment to 
biot@ehnologyp th~t is in th~ form of differ@nt principl~s to b@ appli@d to 
bioteehnologic~l proc~~s~~ ~nd product~ from oth@r foodstuff$p ph~rm~t~uticalsp 
anim~l foodstuffsp ~gritultur~l r®gul~tions or environm®nt~L me~sures ~ th@ 
requirem®nt is for ~n ~ppr~~i~tion th~t when ~t~nd~rd~ ~r~ b~ing ~pplied ~nd 
procedures followed th@ sp~ci~L f@~tur~s of biot~thnology ~~~ll be fully t~ken 
into account in th~ m~nn@r ~et out b@lo~o lhus to giv@ an ~~~ffipl~P clir~ctiv~s 
or n~tion~l l~ws on ~gro=ch@mieal$ would b® ~ppli~d simil~rly to 
biotechnologic~l ~s to oth@r m~teri~lsu Mith th~ provi~o th~t Mh~re ther@ hive 
b@en low limit ~~emptions p~rmitting ~m~Ll=st~le field trialsu outside the 
safety laboratory conditionsp th~~e eu@mptions would not apply in th@ c~se of 
biot~chnolo@it~l m~t~ri~lsu bet~u~e of the ~®ed to ~nsur® th~t t~@re is no 
esc~pe of r@produt~bl@ m~teri~l into th@ ®nvironM@nto f~rthermoreu mar@ 
rese~rch is re~uir@d into th@ tonditions of r~l®~s@ ~nd b@h~~iour of r~N~ 
organisms wh@n r@l~~s@do 
11e It is desir~bl@p in the fir~t pl~tep th~t d@~@lopments in the Unit~d 
Stat~su J~p~n ~ncl Europ~ s~ould go ~long p~rallel lin@s with ~pplic~tion of 
the same g®ner~L principl~~ ~nd procedure~ ~h@r~ po~sibl@a It i~ @~c~~dingly 
important th~t in Europ~ ,t~~lfu th~r@ should b~ ~ t@mffion s@t of re~uir~Ments 
~nd proc@dur®sp th~t th@y should b@ appli@d by ~uthoritiis in th~ ~®mb@r 
St~tes und~r Community dir~ctiV@$ ~h~r@ n@t@ss~ry~ ~nd th~t th~r® $houlci be 
mutu~l recognition of con~@~t~ giv~n by on@ ~®~ber ~t~te in the oth®r~a ~ll 
thes~ obj@ctives ~r@ in f®ct being r@cogni~®d insof~r ~~ bodie~p such ~s the 
OEC~p are bringing togeth@r informed and int~rested opinions ~nd th@re i~ a 
very Larg~ me~sur~s of ~gre@m@nto CUBE1P e~xc2 ~nd ssc3 in th@ 
Commission ~re much involv®d in the$e objettiv@~o 
1cusE = tonc~rt~tion Unit on Biot~chnology in Europe 
2aRIC = Biot~chnology ~egul~tion Int~rd~partm@nt~l tomffiitt~e 
3ssc ~ Biot~t~nology St@~ring tomMitte® 
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much bro~d~r ri~ht b®CILI~@ it ~r©t®ct$ not only th@ ~l~~t& but ~ll itw produc~ 
and a p~t@nt cl~im would und©ubt@dly prot~tt ~~ny ~~ri~nt~ on ~ny p®rtitul~r 
strain p~t®nt@da lh® r~~~on in th® p~$t forth@ @~clY~ion of pl~nt~ ~nd 
anim~ls cre~t@d by bi©logit~L ~~~ns from p~t®nt ~rot~ttion M~$ th~t th~ @ein~ 
were h~ph~z~rd0 b~~~d upon t~@ ~pplic~tion of @@n@tit br@®ciin~ ton~@pts h~rdly 
in ke~ping with th~ pri~©i~l®~ of industrial inv@nti©no 
60 It toulci w@ll 8 h©M@v@r 0 b® ~~icl th~t wit~ biot@chnolo~ical d®v@lopment of 
new species by rn~~ns of g@n@ m~nipul~tion $Uth wor~ f~ll$ Mithin th@ n~tur~l 
printipl@$ of p~t~nt l~~ pr©t@ttion ~sit is b~sed wpon cielib~r~t~ ~pplic~tion 
of scientific principl~$c It i~ t~rtainly th~ C~$@ th~t th@r@ is insuffitient 
protettion for biot@t~nologic~l cl@velopM@nt by r®~son of r~combin~nt ~NA 
(rD~~> and th~t thi$ is~ ~@riou~ dr~wb~c~ to th@ d@~@lopM@nt of 
biotechnologyo It ~ould b@ pos~ibl@ to ov@rcom@ this dr~Mb~e~ if th@ M~mber 
Stat@s of th~ ~unich ton~@ntion d~cl~r~d in ~©MMOn t~~t r~W~ W~$ not~ 
biol it~L processo 1hi$ ~owld ~@~n that proc@~$@$ forth® production of new 
org~n SMS ~ould b~ prot~tt~dp ~nd ~t th@ $@@@ tiffi@ ~~~b@r St~tes ~hould agr~e 
that the inclu~ion of cl@i~s to ~i~ro=org~ni~~$ p~r ~~ (p@rmitted in the 
Convention but not r@eo~ni~@d cl®~rly in ~ll ~@@b~r ~t~t~~a l~g~l $y~t@ms) 
should be ~ct~pt~bl~a Xn thi$ ~~Y ~hortcoming~ in t~@ ~r~s~nt p~t~nt $y$t®~ 
in the EEC coYld b@ o~@rto~@ ~ithout h®~ing to @nd th@ ~Ynich tonvention it 
the present st~g@; whiL~ @t th@ $~~~ tim~ gr~~t@r prot@ction could b~ iffordecl 
to biotechnologyp ~~ i~ no~ th@ C~$@ in the U$~o Th@ ~bs@n~@ of sue~ 
prot@ction is n~t~r~lly ~ ~~riou~ di$~dv~nt~g~ to Europ@~n indu~try~ 
1~ However§ befor@ this st@p i~ t~~~n~ it ~ould b~ net~$$~ry to ~ake ~ 
political d@tision th~t ~rot@ction ©f pl~nt ~nd ~nim~l ~~t@ri~Ls and their 
products is desir~bleo Kn p~tent l~wffe at pr~$®ntp ther~ h~s ~lM~ys b~ 
cert~in degree of @~t~ption giv@n to foodstuffs ~nd m®ditin~$ in m~ny of the 
nation~l l~~s on th~ ground~ of ~oti~l policy~ l~i~ h~$ norm~lly tak~n the 
form of th@ provision th~t th~ ~~t®nt@e ffi@Y ~ot ~r~~@nt th~ produttion of ~uch 
product~ but c~n b@ comp@ll@cl to lit@n©@ t~~ produetion if th@r~ i~ ~ ne~d 
that h~ is not fulfillingo 1~@ Munich ~~t@nt Conv®ntion @nd®d th~ provisions 
for compLilsory litensingp ~nd g@n~r~lly ~P~~king it Ho~ld ~~pe~r th~t it is 
accepted th@t the supply of ph~rm~t@ut1c~l~0 for inst~nC®p ~ad not b~en 
advers@ly affected by this ch~n@@ in th@ l~~o 
Be There have b~en ~ompl~ints in th@ biotec~nolo~y fi®lci in Europ~ recently 
that Europeans suff@r from dis~dv~nt~~~~ in t~~t in J~p~n ~nd t~@ United 
States th@re is~ 0 gr~c@ perioci 0 ~fter ~n inv@ntion h~s be~n m~ci~ during ~hich 
the inventor c~n publish th@ inyention and yet not destroy hi~ right 
subseauently to ~pply for a pat~nta The ~erioci of gr~c~ is not r~~ogniz~ci in 
Europe~n l~Wp ~h®r@ ~ny p~blit~tion befor@ ~pplic~tion for p~t@nt renders the 
patent inv~Lido It i~ tru@ th~t th~ 0 grac~ period 0 do~~ r~nd~r it muth ea$ier 
for university r®se~rch to b@ tr~nsf~rr~cl to industry r~picily bet~use the 
university is not det~rr~d from publishing its r~~ults by th@ n@~d to ~e~p 
s~crecy until~ p~t~nt h~s b@~n ~ppli@d fora It 1$ $~id th~t universiti~s set 
such high important~ on e~rly PLl~litation th~t th~ ~urop®~n sy~t~m i$ ~ 
disincentive to tr~nsfer t~thnolo~y from ~c~demit to indu~trial circlesa 
Howeveru th~ concomit~nt di~~dv~nt~g~ of th@ ~m~ric~n ~y~t@m is t~at there is 
far less cert~inty ~s to th@ own@r$hip of~~ inv~ntionp b@t~us@ it i~ possible 
in th~ United St~t®$ to h~v~ very ~~p@nsiv~ prote@ding~ to d@termine ~ho ~as 
the origin~tor of th@ inv@ntion ~ub~@quently ~ppli®d fora Xn Europe thi$ lack 
of certainty cannot ~nistp b@c~u$~ th® first ~pplit~nt l@~t®pt in very limit~d 
cases of theft of~ confid@ntial dotum~nt) is r~g~rd@d ~$ t~e ~ppropri~te 
pate~teeo 1husp d@~pit@ th@ di~in©@ntiv@ th~t th® l~c~ of~ 0 ~r~ce p~riod 0 is 
said to five in Europ~ to tr~n~f@r froM ~c~d®~it to indw~tri~L cirelesp it is 
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12a Types of biotechnological procedures and products 
(a) In many biotechnological processes live organisms containing rDNA will be 
employed in the production process but the product sold will comprise no 
living or reproducable materials~ In this case the special 
biotechnological hazard is confined to the place of manufacture and here, 
therefore, containment safety regulations will relate to methods of 
manufactures 
(b) Live organisms which will be used by the final user as such outside places 
of manufacture and which are capable of reproduction will require special 
consideration when they carry foreign genes or gene components introduced 
intentionally by gen~tic engineering techniQues. Here the products of 
rDNA must be had in mind. This heading does not include organisms 
(viruses, bacteria, alga~, animalsp plants~ etc.) naturally occurring, or 
the subject of natural or induced mutation, unless foreign genetic 
material has been introduced by biotechnological processes. 
Cc) Manipulation of human genes~ this is an ethical and moral question, which 
is relevant only in the case of certain pharmaceuticals, so far as 
industry is concerned and should be considered entirely separately~ It is 
beyond the scope of this opinion and is being considered by the Committee 
on Legal Affairs and Citizens' Rights in the report currently prepared by 
Mr ROTHLEYe 
The requirements of comoetitive industry in Europe 
13. It is very necessary for industry in Europe to have a degree of cost 
certainty as to the procedures reauried to bring a proposed development for a 
commercial production onto the market : at the present time it is probably the 
case that a good deal of biotechnological developments are deterred by fear as 
to doubts as to what hurdles have to be overcome and whit will be their costs 
and the impracticability of setting up ne~ plant in the face of such 
uncertainties~ 
Use of existing Community and national regulations 
14. Existing Community and national regulations already cover all fields of 
commercial exploitation with reQuirements for safety of humans, animals, 
agricultural processes and the environment, though of course these are 
constantly being updated and developed and environmental standards are 
raised. All these controls and the general reauirements for safety and 
environmental amenity should be applied to biotechnological procedures and 
products in the same way th~t they are applied to other laboratory operation, 
manufacturing plant and operations, experimental testing outside controlled 
conditions and final release upon the open market. In other words, there 
should not be different standards of safety and amenity merely because a 
process or product involves biotechnology. A process of manufacture should be 
as safe to those involved with it and a product should be as safe for the 
public and as appropriate to the environment 9 however it is obtained and 
whatever its chemical or biological make-up may b®a However, as mentioned in 
paragraph 10, the low limit exemptions normal in existing legislation (to 
permit small-scale trials in the open environment) should not be permitted in 
the case of paragraph 12(b) aboveQ 
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Soecial features for biotechnological processes and products 
15. Howeveru in view of the relative new~ess of biotechnological productsp ~nd 
uncertainty as to their possible consequences, it is necessary to superimpose 
upon existing regulatory procedures special assessment of the risks which may 
be involved in order that special conditoins may be laid down to take them 
fully into account. However, because of the great variety of types of 
biotechnological processes and products that may be developed over the next 
few years, it is desirable to treat each proposal on its own merits setting 
out special conditions when requried on a case-by-case basism In order to 
make sure, however, that in each case full consideration is given to all 
possible aspects raised by biotechnological issues it is necessary to lay down 
a framework of procedure for risk assessment. This is being considered by 
industrial representatives in Europe and it would appear that the sort of 
procedure that they have proposed is appropriate4. It would appearu 
however, that the same type of risk assessment should be applied in all 
biotechnological procedures and products, ~herever they are carried out in the 
Community, whether industrial or notm This wouldp therefore, apply to 
universities and other such institutes~ 
16a The proposed risk assessment programme for any particular case would 
comprise certain stages at which risk assessments should be made and certain 
questions asked and answered. The steps proposed are~ 
project initiation, (i) 
(; i) 
(iii) 
( iv) 
(v) 
contained laboratory experiments (in vitro and in vivo)p 
small-scale experiments (closely monitored, non-contained), 
field applicationu and finally 
commercial applicationm 
17. At the first stage, characterization of the organisms must be made for the 
purpose of the procedures to be carried out and an assessment made of the 
containment level that will be reQuired for adeQuate safetyo In each 
subsequent stage, assessment must be made as to that next stage only of: 
Ca) the risks and types of exposure to humansR 
(b) assessment of the capability of the organism to survive, multiply and 
spread, 
(c) the risk and type of exposure of animals (insects, wild animals, farm 
animals) and on various plants, 
(d) interaction with other relevant components of the eco-system, and 
(e) contingency measuresm 
These assessments willp at each stage, lead to a definition for the purposes , 
of carrying out that stage of the safety precaution measures necessary for 
workersp experimental design and monitoring systems, definitions of safety and 
precaution measuresp estimation of the potential consequences on release and 
measures for risk minimization in the case of unforeseen eventsQ Quite 
clearly, each of these risk assessments and required steps to meet them will 
have a different significance according to the stage that is being considered. 
4rhe European Committee on Regulation Aspects of Biotechnology which 
considered guidelines laid down by the OECD 
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Procedures 
19w If the above form of uniform reporting by proposed users of 
biotechnological processes or products were adopted, this ~ould Lead to a 
common system of consideration ~nd grant of consent to carry out 
biotechnological proc~sses or to produce products throughout the EECe A 
common form of reporting would also make it easier for the relevant 
authorities to monitor the sssessm~nt of risks ~nd lay down the necessary 
conditions for meeting themo It would also mean that mutual recognition of 
the consent given by one authority ~ould be readily comprehensible to the 
authorities in other Member States~ 
Labelling 
20a Existing labelling regulations in the EEC should be equally applicable to 
biotechnological as to other productsv any special conditions required in the 
final stage 8 or any necessary previous stagep could be established during the 
risk assessment set out aboveo 
Transoort 
21~ Regulations for the safety of transport of dangerous substances would be 
the same as for any other d~ngerous chemical substancesm Though here again, 
if there were requirements for special conditions at the Last or any 
intermediate stage of risk as~essment§ these should be Laid down by the 
authority considering the riskso 
Frontier controls 
22s There should be no nec~ssity for ~ny frontier controls other than those 
that exist for other inherently dangerous products within the EEC, and ideally 
these controls should not be based upon the existence of frontiers but on 
reporting and monitoring of the starting pointg route and destination of the 
journey with appropriate reports on monitoring by the authorities 
geographically involv~de Cl~~rly it is important to ensure that barriers to 
trade within th~ EEC are not set up under the guise of safety requirements for 
biotechnologic@l reasons~ 
Exports 
23® Conditions laid down in the final stage of the risk assessment to meet 
release of a product to the public, should ~pply also to exports to other 
parts of the world1 most notably, of coursep the under-developed world in 
order to avoid exploitation of possibly more l~x safety and environmental 
regulations in Third World countries@ 
CONCLUSIONS 
24Q Two major legal aspects of the development of biotechnology (excluding the 
moral and ethical probl®ms of man1pul~tion of hurn~n genes) ~xist : patent 
problems and safety and environment regulatory problems~ 
25~ Patent problems greater certainty in patent protection to biotechnology 
is vital for European industry: 
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Ci) there is doubt as to the patentability of micro-organismsp firstly 
because the practical difficulty of sufficiently identifying a 
micro-organism in words renders obtaining valid patent rights 
doubtful. Therefore, the Member States and the Community should adopt 
the mechanism of deposit of micro-organism by the patent applicant as 
sufficient for patent purposes together with access to the deposit by 
the public through the intermediary of an independent expert for the 
purposes of obtaining sufficient identification and information to be 
able to repeat the inventions 
(ii) there is, secondly, doubt as to the patentability of micro-organisms 
because of the exclusion from patent protection of plants and animals 
created by biological meansm In view of the clear inventiveness of 
recombinant DNA gene engineering the Member States and the Community 
should accept that such gene engineering does not fall within the 
exception to patents for plants and animals created by biological 
means~ and that micro-organisms per se can be the subject of patent 
protection. 
Ciii) although the European rule that publication of an invention before 
application for a patent invalidates the patent (unlike in the USA and 
Japan, where a period of grace after publication is permitted before 
application)R and although this is possibly a disincentive to academic 
disclosures to industry, it is not clear that the USA/Japanese system 
should be adopted, because of the costly disputes that this system 
creates with regard to who first made an inventiona 
26. Regulation for safety and the environment concerning processes of 
production and products involving micro-organisms carrying foreign genes or 
gene components introduced intentionally by genetic engineering techniques. 
Clarity and certainty in the regulatory procedure are vital for European 
industry. 
Ci) The criteria in existing regulations on safety and the environment 
should apply to biotechnological processes and products as they do to 
chemical processes and productsc 
(ii) At present a case-by-case examination and granting of approval should 
be applied to biotechnological processes and products in view of the 
very varying issues arising in different fields~ 
(iii) Low Limit exemptions for small-scale field trials common in regulations 
on chemical processes and products should not be permitted for 
biotechnological processes and products~ 
(iv) All regulations should be harmonized in the Community, they should be 
implemented by Member States with mutual recognition by the others of 
consents and conditions given by one Member State~ 
Cv> Special risk assessment on a case-by=case basis shall be made at each 
stage of development of projects (initiation, contained Laboratory 
experiments, small-scale non~contained experiments, field application, 
commercial application> and safety and environmental conditions should 
be established for each step again on a case by case basis based on 
such assessments9 
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Cvi) The risk assessment procedure should also apply to non-industrial 
projects in universities, research establishments, etc. 
(vii) Further research is particularly necessary at a Community level on the 
problems of release and containment of micro-organisms. 
(viii) Labelling, transport and export activities should be subject to 
conditions Laid down in the risk assessment procedure. 
(ix) The nature of biotechnological products should not be used as a means 
of perpetuating internal frontier barriers: the safety of transport 
should be monitored at start and destination of journey and along the 
route, not specifically at internal frontiers • 
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AQ Definition of the problem 
1m Viewed from the perspective of the Committee on the Environment, Public 
Health and Consumer Protection, any discussion on the future of biotechnology 
must answer the following questions: 
(a) Is the growth in our knowledge of the possible risks of biotechnology 
keeping pace with the growth in the use of that technology7 
(b) Does biotechnology ent~il risks ~hich, going beyond localized accidents, 
could adversely affect th® environment and evolution overall? 
(c) Will the underlying rationale of business and research automatically allow 
biotechnology to be developed in areas where the social need is great but 
the economic interest scant? 
This opinion will not discuss whether it is ethically defensible to apply 
genetic engineering to human beingsa The committee will give its detailed 
views on that subject when Mr ROTHLEY draws up his report. 
2e Knowledge of the risks of biotechnology has not progressed very far to 
datea Since the Asilomar Conference in 1974 only a few studies have been 
conducted to evaluate the possible risks and consequences of gene manipulation 
for human, animal and plant life and the environment in general. Once 
positive evidence had begun to emerge that genetic engineering was 'feasible', 
interest in Questions of safety subsided dramatically. As a result, there is 
an increasingly yawning gap between the development of biotechnology and 
knowledge of its risksa 
3. Environmental problems associated with the release of genetically 
manipulated organisms 
Basically, there are three questions which have either not yet been fully 
answered or else cannot be answered at all 
(a) Could the course of evolution be influenced by small quantities of 
genetically engineered organisms that had been deliberately released? 
(b) What, if anything, might be the consequences of the massive application of 
such organisms? 
Cc) Could organisms which had inadvertently found their way into the 
environment, i.e. as the result of an accident, influence the course of 
evolution? 
The experimental release of plants or animals appears relatively safe. The 
auestion here is whether the artificial organisms would be capable of finding 
their way independently into the environment and eliminating potential natural 
rivals. That would throw entire ecosystems out of balance. Theory and 
practice both seem to rule out this possibilitya The new properties created 
in plants and animals will be geared to human food requirements. Yet what is 
beneficial to man is beneficial to neither the plants nor the animals - if 
anything, Quite the reverse~ The properties acquired through gene 
manipulation are unnecessary for, or even a hindrance to, survival in the 
harsh natural environments On the other hand, the situation as far as 
micro-organisms are concerned is still completely unclears Yet of all things, 
the release of micro-organisms is currently being tested. Naturally occurring 
bacteria, for instance Pseudomonas syringae and Pseudomonas fluorescens, are 
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to be suppressed by genetically manipulated species. The natural bacteria 
secrete proteins which, because of an affinity between their crystal lattices 
and those of frost, can act as crystallization centres the ipremature~ 
formation of ice on plants (e.gu strawberries). The genetically manipulated 
species do not have this property. If sprayed on strawberry fields, the 
artificial bacteria could drive out the natural ones and thereby protect 
plants from frost. However, it is feared that the effect cannot be confined 
to the sprayed fields. If that were the case, then weeds - hitherto 
maintained in natural balance by prevailing temperatures= might also be 
protected from frost. 
4. The mass 
prob ems. T 
experimental 
anisms raises even more 
etween this and 
The purpose of massive applications is economica The genetically manipulated 
organisms are there to produce a profit. The presence of natural rivals runs 
counter to the economic interests of the persons who released the artificial 
organismsd 
- Massive applications lead to the standardization of varietiesa large tracts 
of land which used to house many varieties are being made over to a single 
variety. 
- Massive applications, as opposed to experiments, increase the probability 
that organisms will escape into the neighbouring environmentm 
- In crop breeding, independence from artificial fertilizers and resistance to 
pests are the most desirable properties to aim for. With massive 
applications, an wepidemic' spread beyond the areas under cultivation can no 
longer be ruled out. 
The unintentional release of dangerous micro-organisms was the subject which 
sparked off discussions on the possible risks of genetic engineering. The 
discussions on safety in recent years have partly dispelled such doubtsc Yet 
certain imponderables remain 
- a micro-organism cannot be equally harmful in a large number of 
fundamentally different biotopes. A general risk to the environment is 
therefore excluded. In contrast, mankindp with its culturally acquired 
independence from environmental conditions, affords a uniform ecological 
niche for potential new pathogens@ 
Naturally occurring gene transfers could pass on dangerous characteristics 
to what were previously harmless bacteria= 
- In theory, a mass release could alter the above view: nature can cope with 
mutations and sudden variations in individual genes, but not with anything 
on such an immense scalem 
5. Tampering with genetic potential may also lead to species becoming 
extinctm The danger here stems from two causes~ 
- The gene pool might be fatally impoverished, owing to a lack of knowledge. 
- If biology, ~ith its hitherto autonomic system of laws, is made subject to 
the laws of human society, the 'rules of the game' obtaining in human 
society will be imposed on naturem 
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Thes~ outst~nciing probl~m~ mu$t b@ tl@rified b~for~ g~n@tic engine®ring is 
applied on~ larg~ scilea ~s f~r ~~ medic~l r~~eijrth i~ conc@rned§ the 
e~peri~n~~ acquir~d in t~~ Co@munity res~~rt~ pro@r~mm~ ~ill b~ th~ best 
guid~o 
In the d~b~te on the multi~~nu~l r~~®~rch ~ttion progr~mm~ in the field of 
biotechnology (19t5=19!~) 0 th@ Europ@~n ~irli~ment c~lled for e~ph~sis to be 
pl~c~d on h~~lth 0 environ~@nt~l prot@ttio~ ~nd ris~ r~se~reh0 ~s w~ll ~~ on 
reducing production eo~t~Q 1h~ Couneil h~$ ~dopted ~ll P~rli~m~nt 0 s 
a~endm~nts to th~t ~ff~tto lh~r@ i~ thus ~lr~~dy ~ bro~d basi~ for ~ctiono 
In th~ cloning of V@tcin@s ~nci hormon~s 0 it i~ v@t~rin~ry ffi~dicin~ ~hich is 
the main focus of ~ttivitya N~v~rth~les~p 13 out of th~ 22 r~s~~rch projects 
also hav@ potenti~l applit~tion~ in hum~n M~dicin@ {@aQo th@ blood clotting 
f~ctor)a tell cultur@ r®~®~rth too h~s m~dic~l ~pplic~tionso 
Only 24 out of 78~ r@$@~rth proj~ct~ {3%) touth@d on this ~ubj~cto The 
release of gen~tic~lly m~nipul~t~d micro=or~~nis~s i~ the m~in probl@m under 
consid~r~tion in th~ r~$®~rt~a 
Pr~ctic~l e~p~rience with th@ progr~mm@ so f~r point$ to~ h@~vy bias to~ards 
industryp M~ile th~ soei~lly im~ort~nt ~r@~$ of h@~lth and t~~ ~nvironm~nt are 
not b~ing giv®n th~ir du~a Yh~ C©mmi~sion 9 how~~~ru t~nnot b~ blam~cl for 
this~ ~part froffi th~ progr~m~e ~dvi~ory eommitt~e~p the priorities selected 
by res~arc~ers th@mselve~ c~rry ~ good d@~l of ~~ighto S~f~ty r~se~rch does 
not enjoy a very high reput~tion ~it~in the ~ti@ntifit community ~nd is no 
passport to ~n at~deMit c~reer~ This is~ vi@hl ~lso ~h~red by researchers 
thems~lvesQ According to th® ~@ll ~nown gen~tic engine@ring $pecialist 
Prof a ~ra Werner Gobelp b~eteri~l @cology is r~lativ@ly neglect~d because 0you 
don°t ~in ~obel pri2es for it th@se d~ys 0 ~ Mh~t is mor~u in medical 
applications of biot~c~nologyp th~ logic of th~ m~rk~t do~~ not necessarily 
reflect the soci~l n®@do 
7~ Th@ effort~ mad~ by th® Community so f~r ~re not suffiei~nt to close the 
newly Midening g~~ betw~~n t~® growi~g ~pr~~d of biotechnology ~nd an adeQuate 
knowledge of th~ ~~soti~t~d risksG 
So The tommunity 0 s acti~iti~$ ~r® l@ss th~n fully @ffetti~~ in encour~ging 
socially desir~ble m@dical ~nd @nvironm~nt~l ~pplic1tion~ of biot@chnologyu 
although th@ l@g~l b~$i~ for suth ~pplie~tions ~lr@~dy @~ist$o 
9~ The ~@~kn®SS~$ obs®rv~d in th~ c~s~ of th~ to~ffiunity ~lso applyu for the 
s~me r~asons& tot~® ~ttivit~~ of th@ ~®ffib@r ~t@tesa 
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100 Solving s~f@ty probl@~~ i~ ~n @~in~ntly $Uit~bl~ t~$~ forth~ Communityo 
Given that offers to ~po~~or r~~~~r~h ~r~ tl~~rly not ~nou;~ (ot~~r ~ubj~ets 
~re 
0 Mor~ ~ttr~tti~@ 0 )o ffl©r~ ciir~tt ~ppr©~~h~~ will h~~t to b~ eMploy~do Th@ 
s~me appli@~ tot~@ fi®ld~ of ~~dieine ~nd th@ @nvironm~nto ~$ M@~n$ to this 
end9 th@ toMfflunity could 
Moreover th@ furop@~n P~rli~~@nt h~$ r@t~~tly ~@t up ~n offit~ forth~ 
as~eS$ffl@nt of $Ci@ntifit ~nd t@ehnologie~l ©ption~P ~bbr~~i~t@d ~~ 0 ST@~ 0 o It 
would seem p~rtitul~rly ~ppropri~t@ to t©~$ult thi~ body whit~ i~ dir~~tly 
an~Mer~bl® to P~rli~~@nt on t~® @ff@tt~ on publit he~lth ~nd th~ ®nvironment 
of th~ u~e of biot~thnologyo 
i1o 1~e instryment~ r@~uir@d ~r@ n@ith~r ~sp@ti~lly origin~l nor new forth~ 
tommunityo They h~v~ lon~ b@@n @PPli@d in th~ @n~rgy ~ettoro Wh~t is 
import~nt i~ r~th®r to us~ t~~m f©r biot~chnolo~y ~s ~~lla 
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